Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.
about
From palliative therapy to prolongation of survival: (223)RaCl2 in the treatment of bone metastasesFuture directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS)Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerTargeting Bone Metastases in Metastatic Castration-Resistant Prostate CancerTumor cell dormancyBone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myelomaThe best of both worlds - managing the cancer, saving the bone.Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies.HIF targets in bone remodeling and metastatic disease.Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case reportHealth resource utilization associated with skeletal-related events: results from a retrospective European studyImprovement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab.Cancer and the metastatic substrate.Hemin activation of innate cellular response blocks human immunodeficiency virus type-1-induced osteoclastogenesis.'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer.New cancer therapies and jaw necrosis.Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer.Mechanisms of Therapeutic Resistance in Prostate Cancer.Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience.The treatment patterns of castration-resistant prostate cancer in Japan, including symptomatic skeletal events and associated treatment and healthcare resource use.Therapeutic management of bone metastasis in prostate cancer: an update.Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures.Spinal Metastatic Disease: A Review of the Role of the Multidisciplinary Team.Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?Racial variation in the clinical and economic burden of skeletal-related events among elderly men with stage IV metastatic prostate cancer.Understanding the molecular mechanisms driving metastasis.Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark.The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials.Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.The Biology and Therapeutic Implications of Tumor Dormancy and Reactivation.Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.Choosing a better end point for trials of bone-protective agents.Assessing the benefit of bone-targeted therapies in prostate cancer, is the devil in the end point's definition?Percutaneous Balloon Kyphoplasty Vertebral Augmentation for Compression Fracture Due to Vertebral Metastasis: A 12-Month Retrospective Clinical Study in 72 Patients.Androgen Receptor-CaMKK2 Axis in Prostate Cancer and Bone Microenvironment.Severe Hypocalcemia and Hypomagnesemia with Denosumab in Advanced Chronic Kidney Disease: Case Report and Literature Review
P2860
Q26740064-8081F8F4-4AA1-4C76-9EA9-37087433D5C2Q26747566-BBA8BF8D-B5C1-4FE1-8EAE-1103B7FEF188Q26747782-D0658152-EF0E-49E1-99DD-2314FF270FF7Q26752785-3F04597D-5B27-4CD0-830B-32801853EC7CQ28073065-EFF93D19-73FD-4941-957C-E0B07A666144Q28081996-EE5924DA-98EF-4A3D-9934-2DA01B1E2B84Q33920055-7A4A3EF7-BA66-4028-9E8C-E37C9E231E52Q35087364-FF33D2E3-CDB4-42F8-993D-C8672D88E5CAQ35554344-20B5F990-8D37-4F23-8DBD-83D86D4B8BD8Q35721588-C9B00C2B-D1AC-4697-8F43-78B6B251925CQ36985287-6E7CA148-9919-46CC-9B52-DE63718C6444Q37443111-23ADDB30-F796-48C4-8563-961DD46E51B9Q37573461-2DF56771-0E09-4A47-8B00-C7257D75B8D9Q37602723-15D7CA51-5CBB-48F3-B5B2-DA95D4210A1EQ38366829-620D607F-DF88-4403-8A0F-3F58E635E458Q38584982-43C79D09-9201-4DC2-9961-C7B8EFEE4654Q38640455-6F78239B-BBBA-49BC-96A5-DCCE96CD0163Q38754316-6B65D274-67CF-4866-87EC-F56176B0A993Q38777682-015F2151-D009-44F4-B4E0-16F85A11D9D6Q38845259-E1358836-667D-497A-93AB-25FB4C02A138Q38917844-8346C69D-1C75-47E4-965D-1EBBEC056D85Q38964037-66ACE7F7-FC3F-4685-91D6-35E116D65631Q39013177-50935F52-C105-43D0-9DA2-BBFB700E972AQ39155149-9E899810-5B6A-46EC-B9E0-FFDB27D1C35DQ39633099-E04DCB83-E2DC-41ED-8BB7-F5EFF883CCD2Q41147765-F420846C-A63D-4904-B752-B3FAF400C911Q42353406-FA415CCC-7017-4F9D-927D-5EB19A8CA35CQ42373317-554EAA7A-255A-47FB-A84C-B8731435D916Q47132177-DE2B146C-48AA-4374-B5B8-167B42BBFDF6Q47563547-3D7EE138-FB03-4EF7-B70B-B904D83EAB30Q50661701-6C258021-66D2-4DDD-9529-91E904F8C793Q52608415-406DB370-B221-4F11-BA2A-FDB9554953C0Q52778839-F013686F-F876-4C27-9723-B75936AE17AEQ53632650-D2BED084-8C13-449E-9B11-CEF486AF8092Q53675120-3D12FB23-1507-4837-9E48-7B83A62867E7Q55406280-69C936F8-3A59-44A4-9CD0-BDCAFCAD9264Q55500622-2EAF33B2-2870-4F19-85A7-A3D145B176BBQ58567262-16A0304A-44F8-46A5-B5F3-F9FDBA11C4A8
P2860
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Denosumab for the prevention o ...... d symptomatic skeletal events.
@en
Denosumab for the prevention o ...... d symptomatic skeletal events.
@nl
type
label
Denosumab for the prevention o ...... d symptomatic skeletal events.
@en
Denosumab for the prevention o ...... d symptomatic skeletal events.
@nl
prefLabel
Denosumab for the prevention o ...... d symptomatic skeletal events.
@en
Denosumab for the prevention o ...... d symptomatic skeletal events.
@nl
P2093
P2860
P356
P1433
P1476
Denosumab for the prevention o ...... d symptomatic skeletal events.
@en
P2093
A Balakumaran
R E Coleman
P2860
P304
P356
10.1093/ANNONC/MDU519
P577
2014-11-25T00:00:00Z